Loading provider…
Loading provider…
Medical Oncology Physician in Tampa, FL
NPI: 1093915704Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D., PH.D Joseph's Phone Numberphone_androidMobile
Get M.D., PH.D Joseph's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2015 - 2027
OH State Medical License
2007 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology

American Board of Preventive Medicine
Clinical Informatics
Ohio State University Hospital
Fellowship • Hematology and Medical Oncology
2010 - 2012
Residency • Internal Medicine
2007 - 2010
University of Maryland School of Medicine - Baltimore
medschool.umaryland.edu
Medical School
Until 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 84 | 148 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 28 | 28 |
Authors: Zeynep Eroglu, Nikhil Khushalani, Patrick Hwu, Ahmad Tarhini, Andrew Brohl
Journal: Support Care Cancer
Publication Date: 2024-05-06
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.
Authors: Zeynep Eroglu, Nikhil Khushalani, Vernon Sondak, Ahmad Tarhini, Amod Sarnaik, Andrew Brohl
Journal: Mol Cancer Ther
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: DRUG: Ipilimumab, DRUG: Nivolumab, RADIATION: Stereotactic Body Radiation Therapy (SBRT)
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Regeneron Pharmaceuticals
Intervention / Treatment: DRUG: Cemiplimab-Rwlc
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Regeneron Pharmaceuticals, Sanofi-Synthelabo
Intervention / Treatment: DRUG: Cemiplimab-Rwlc